On the 29th, the eighth batch of centralized procurement of drugs organized by the state produced the proposed winning results in Lingshui County, Hainan Province. After the public announcement, the official winning results will be released. The purchase of 39 drugs in this centralized purchase has been successful, and the average price of the selected drugs will be reduced by 56%. Based on the agreed purchase volume, it is estimated that the annual cost savings will be 16.7 billion yuan. According to reports, pharmaceutical enterprises actively participated in this centralized procurement, with 366 products from 251 enterprises participating in bidding. 252 products from 174 enterprises have been eligible for the proposed selection, including 5 products from 5 international pharmaceutical companies and 247 products from 169 domestic pharmaceutical companies. The proportion of successful bidders is approximately 70%. An average of 6.5 enterprises were selected for each variety, further enhancing supply diversification and stability. This centralized purchase covers drugs for common and chronic diseases such as anti infection, cardiovascular and cerebrovascular diseases, anti allergy, and mental diseases. The average price reduction of oseltamivir phosphate dry suspension for the treatment of influenza A is 83%, which will significantly improve the availability of antiviral drugs. In particular, the price of a batch of antibacterial drugs has been effectively reduced, removing the economic drivers of antibiotic abuse, and promoting rational clinical medication. The commonly used antihypertensive drug amlodipine and atorvastatin calcium tablets reduced their price by 48%. In addition, the price of a single dose of Atoxiban injection for the treatment of premature delivery exceeded 1000 yuan before the centralized purchase. This centralized purchase decreased to an average of 240 yuan per dose, a decrease of 80%, and the burden on patients was significantly reduced. Since 2018, the National Health Insurance Bureau has carried out the centralized purchase of eight batches of nationally organized drugs, including 333 drugs, with an average decrease of over 50%. Next, the National Health Insurance Bureau will work with relevant departments to guide local and selected enterprises to implement the selection results, ensuring that patients will use the selected products after the price reduction in this centralized purchase in July 2023. (Liao Xinshe)